Boston, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a privately held company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine products announced today that the Company has filed a patent for systems and methods for predicting treatment outcomes from chemotherapy.
“This patent application establishes a large opportunity for the company in developing a portfolio of precision medicine products designed to reduce the trial and error of treatment decisions in very expensive areas of modern medicine,” said Carl de Moor, PhD, Inform Genomics Chief Technology Officer.
Ed Rubenstein, MD, President and CEO of Inform Genomics added, “the filing of this application represents the culmination of five years of work by our company and is a major value creating milestone for our stockholders. We believe this, together with the recently licensed patents from National Cheng Kung University, represent major assets of our company and set the foundation for us to be leaders in the precision medicine marketplace. We look forward to working with the USPTO as they review our application.”
About Inform Genomics
Inform Genomics, Inc., is a privately held company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine products that are designed to predict, with a high degree of precision and accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions.
The Company’s lead development program is in oncology supportive care, with two product candidates currently in development: Oncology Preferences And Risk of Toxicity (OnPART™) and Hematopoietic Stem Cell Transplant (HSCT)/Mucositis™.
About the Product Candidates
OnPART™ is designed to accurately predict, in advance of chemotherapy, the risk for six clinically significant and costly chemotherapy-related side effects--moderate-to-severe: nausea and vomiting, diarrhea, peripheral neuropathy, oral mucositis, cognitive dysfunction, and fatigue. It not only incorporates genomic risk for side effects, but also offers a unique feature (Preference Assessment Inventory© tool) that quantifies a patient’s willingness to tolerate these side effects.
HSCT/Mucositis™ is designed to help identify which patients are at high risk for developing oral mucositis (i.e., debilitating mouth sores), a common side effect resulting from high-dose chemotherapy conditioning regimens used prior to stem cell transplantation. Understanding who is at risk for oral mucositis in advance of these conditioning regimens will help physicians plan primary prevention strategies (e.g., use of palifermin or dose modification), thus reducing the patient, clinical, and economic burden of this serious side effect.
For more information, please visit www.informgenomics.com.
CONTACT: Inform Genomics Ed Rubenstein, MD, President and CEO erubenstein@informgenomics.com 101 Federal Street Suite 1900 Boston, MA 02110
Help employers find you! Check out all the jobs and post your resume.
